22 August 2012
Vol 4, Issue 148
  • Contents

    • Focus

      • It Ain’t Over ‘Til the Fat Lady Sings

        The antiatherogenic drug nicotinic acid (niacin) has antidyslipidemic effects independent of free fatty acid suppression mediated by its receptor HCA2 (GPR109A) (Lauring et al., this issue).

    • Research Articles

      • Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

        GPR109A is not the target mediating niacin’s lipid efficacy and the free fatty acid hypothesis does not explain niacin’s mechanism of action.

      • Tracking a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae with Whole-Genome Sequencing

        Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing revealed its origin and probable modes of transmission.

      • Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling

        Blocking BCL9/β-catenin interaction with a stapled peptide inhibits Wnt-dependent transcription and suppresses growth and metastasis in colon cancer and multiple myeloma.

    • Review

    • Editors' Choice

      • A Breath of Fresh Alveoli

        A case report suggests that the adult human lung is capable of partial regrowth after lung resection.

      • Microbial Manipulation of Metabolism

        The human gut microbiome changes during pregnancy and resembles that associated with metabolic syndrome.

About The Cover

Cover image expansion

ONLINE COVER Immunology, Meet Engineering. As translational immunology delves deeper into mechanism, there is a desire for quantitative, design-based bioengineering tools to aid in not only understanding human disease, but also treating it. In this issue of Science Translational Medicine, Swartz et al. discuss the budding relationship between engineers and immunologists by reviewing various opportunities for collaboration in the emerging field of "immunoengineering." In one vaccine-related example depicted on the cover, nanoparticles carrying antigen (red, orange, and blue) can be taken up by antigen-presenting cells in target tissues before traveling through lymphatic vessels (in green) to the lymph node. [CREDIT: Y. HAMMOND/SCIENCE TRANSLATIONAL MEDICINE]